Drugs / CD19&CD20 bispecific CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06503094 | Jan 2024 → Dec 2025 overdue | B-cell acute lymphoblastic leukemia | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19&CD20 bispecific CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06503094 ↗ |
| Modality | Cell therapy | “CAR-T ( chimeric antigen receptor T cell) therapy” NCT06503094 ↗ |
| Route | Intravenous | “by intravenous infusion on day 0” NCT06503094 ↗ |
| Target | CD19 | “recognize CD20 or CD19” NCT06503094 ↗ |